ADBiotech Co., Ltd. (KOSDAQ: 179530)
South Korea
· Delayed Price · Currency is KRW 2,710.00
+85.00 (3.24%)
Dec 19, 2024, 2:09 PM KST
ADBiotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 8,799 | 10,472 | 10,632 | 11,840 | 9,815 |
| Other Revenue | -0 | -0 | -0 | -0 | - |
| Revenue | 8,799 | 10,472 | 10,632 | 11,840 | 9,815 |
| Revenue Growth (YoY) | -16.24% | -1.50% | -10.21% | 20.63% | - |
| Cost of Revenue | 5,658 | 7,282 | 7,520 | 6,831 | 5,416 |
| Gross Profit | 3,141 | 3,190 | 3,111 | 5,009 | 4,400 |
| Selling, General & Admin | 5,765 | 6,212 | 6,284 | 5,333 | 4,369 |
| Research & Development | 1,469 | 1,486 | 1,111 | 550.16 | 788.46 |
| Other Operating Expenses | 153.79 | 147.27 | 126.59 | 119.71 | 68.94 |
| Operating Expenses | 7,591 | 7,963 | 8,095 | 6,564 | 5,396 |
| Operating Income | -4,451 | -4,772 | -4,984 | -1,555 | -996.2 |
| Interest Expense | -540.37 | -426.4 | -124.68 | -130.23 | -579.54 |
| Interest & Investment Income | 99.6 | 149.67 | 6,019 | 5.73 | 9.55 |
| Currency Exchange Gain (Loss) | -20.28 | -38.62 | -39.66 | 64.42 | -42.65 |
| Other Non Operating Income (Expenses) | -822.59 | -813.25 | 1,435 | -777.68 | -5,992 |
| EBT Excluding Unusual Items | -5,734 | -5,901 | 2,306 | -2,392 | -7,601 |
| Gain (Loss) on Sale of Investments | -2,916 | 3,023 | 390.47 | -24.16 | 75.36 |
| Gain (Loss) on Sale of Assets | -2.68 | - | - | 1.82 | 2.27 |
| Asset Writedown | -2,580 | -2,580 | - | - | - |
| Pretax Income | -11,233 | -5,457 | 2,696 | -2,415 | -7,476 |
| Income Tax Expense | -38.37 | -25.58 | - | 249.77 | -131.32 |
| Earnings From Continuing Operations | -11,194 | -5,432 | 2,696 | -2,664 | -7,345 |
| Minority Interest in Earnings | 2,713 | 2,568 | - | - | - |
| Net Income | -8,482 | -2,863 | 2,696 | -2,664 | -7,345 |
| Net Income to Common | -8,482 | -2,863 | 2,696 | -2,664 | -7,345 |
| Shares Outstanding (Basic) | 9 | 9 | 9 | 8 | 5 |
| Shares Outstanding (Diluted) | 9 | 9 | 10 | 8 | 5 |
| Shares Change (YoY) | -9.99% | -9.33% | 31.17% | 53.77% | - |
| EPS (Basic) | -927.95 | -313.27 | 297.39 | -346.68 | -1469.52 |
| EPS (Diluted) | -928.00 | -313.27 | 118.54 | -347.00 | -1470.00 |
| Free Cash Flow | -342.33 | 75.03 | -9,319 | -5,747 | -6,308 |
| Free Cash Flow Per Share | -37.45 | 8.21 | -924.41 | -747.71 | -1262.15 |
| Gross Margin | 35.69% | 30.46% | 29.26% | 42.31% | 44.83% |
| Operating Margin | -50.58% | -45.57% | -46.88% | -13.13% | -10.15% |
| Profit Margin | -96.39% | -27.34% | 25.36% | -22.50% | -74.83% |
| Free Cash Flow Margin | -3.89% | 0.72% | -87.65% | -48.54% | -64.27% |
| EBITDA | -3,321 | -3,639 | -4,258 | -903 | -815.11 |
| EBITDA Margin | -37.74% | -34.75% | -40.05% | -7.63% | -8.30% |
| D&A For EBITDA | 1,130 | 1,134 | 725.66 | 651.6 | 181.09 |
| EBIT | -4,451 | -4,772 | -4,984 | -1,555 | -996.2 |
| EBIT Margin | -50.58% | -45.57% | -46.88% | -13.13% | -10.15% |
| Advertising Expenses | - | 1.06 | 344.51 | 271.87 | 8.37 |
Source: S&P Capital IQ. Standard template. Financial Sources.